Physician profile
Alex Quach
NPI 1104488634
$2,072.70
in general payments reported to CMS, 2019-2025
14 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $562 · 2023: $337 · 2024: $547 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $725.84 | 2021-2025 | Total30, Rocklatan, Dailies |
| Bausch & Lomb Americas INC. | $597.80 | 2022-2025 | Miebo, Xiidra, Infuse |
| Tarsus Pharmaceuticals, INC. | $253.58 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2021 | |
| Oyster Point Pharma, INC. | $65.88 | 2023-2024 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $64.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $46.18 | 2022-2023 | |
| Abbvie INC. | $45.69 | 2022-2023 | |
| Rxsight INC | $29.15 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Genentech USA, INC. | $28.33 | 2024 | Vabysmo |
| Exelixis INC. | $26.98 | 2025 | Cabometyx |
| Biotissue Holdings INC. | $24.61 | 2022 | |
| Coopervision INC. | $19.73 | 2025 | Clariti Contact Lens |
| Apellis Pharmaceuticals, INC. | $19.41 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Quach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.